Company news

Karyopharm Therapeutics Inc. news in 2020

Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.

View company

Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

December 17, 2020

Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 14, 2020

Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma

December 10, 2020

Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting

December 6, 2020

Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2020

Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet

November 11, 2020

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting

November 3, 2020

Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma

November 1, 2020

Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020

October 25, 2020

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19

October 5, 2020

Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020

September 13, 2020

Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors

August 30, 2020

Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

August 3, 2020

Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020

July 27, 2020

U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

July 19, 2020

Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research

July 16, 2020

Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)

July 13, 2020

Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology

June 23, 2020

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

June 21, 2020

Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

June 8, 2020

Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program

May 25, 2020

Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

May 19, 2020

Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society

May 12, 2020

Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

April 28, 2020

Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020

April 27, 2020

Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19

April 19, 2020

Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

March 16, 2020

Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer

March 11, 2020

Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

March 5, 2020

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

March 2, 2020

Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock

March 1, 2020

Karyopharm Appoints Richard Paulson to its Board of Directors

February 27, 2020

U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

February 18, 2020

Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel

February 10, 2020

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 2, 2020

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update

January 12, 2020

Calls in 2020

Decks in 2020